ImExHS (IME) Q1 2026 TU earnings summary

Executive summary

• Q1 FY26 marked a strong start with revenue and earnings ahead of plan, driven by a strategic pivot to an AI-native, agentic radiology workflow platform.

• Five proprietary AI agents are in development, with two live, one in final testing, and two in active development, positioning the platform as structurally differentiated.

• Key software contracts were secured, including significant deals in Colombia and Peru, and the Aquila+ platform is now commercially live at eight sites.

• Leadership team strengthened with new CTO and VP of Global Sales, and COO transition completed.

Financial highlights

• Q1 FY26 revenue reached $7.9m, up 13% year-over-year and 12% on a constant currency basis.

• Underlying EBITDA was $0.8m, up from $0.1m in the prior corresponding period.

• Annualised Recurring Revenue (ARR) stood at $34.8m, up 11% year-over-year; software ARR was $11.1m.

• Cash at 31 March 2026 was $2.5m, down from $3.3m at 31 December 2025; net cash used in operating activities was $0.5m.

• Debt remained flat at $0.5m compared to the previous quarter.

Outlook and guidance

• Expects to exceed FY25 underlying EBITDA and be cash positive for FY26.

• Software revenue growth anticipated to outpace FY25, with stronger performance expected in H2.

• More specific guidance to be provided at half-year results in August 2026.